Non-invasive Biomarker In Prediction Of Cancer Colon in Ulcerative Colitis Patients

Background & Aims: Ulcerative colitis (UC) is one of chronic inflammatory disease and usually associated with colorectal cancer (UC-CRC) and accounted for up to 5% of all CRC. Plasma miR-21 and miR-92a levels used as diagnostic, prognostic and predictive biomarkers and used to differentiate between patients with irritable bowel syndrome (IBS), ulcerative colitis (UC), and colorectal cancer (CRC). Our Aim to evaluate the predictive and diagnostic value of Plasma miR-21 and miR-92a levels to differentiate between patients with UC and UC-associated colorectal cancer (UC-CRC) Methods: A retrospective study was conducted on 120 patients and 20 healthy control and classified into three groups Group (I): 40 patients with ulcerative colitis (UC), Group (II): 40 patients with colorectal cancer (CRC), Group (III): 40 patients with ulcerative colitis complicated with colorectal cancer (UC-CRC) and 20 healthy control. Results: Females were predominant among UC (67%) or UC-CRC (60%), family history of UC and CRC more common in UC-CRC group. Expression levels of the miR-21a and miR-92a were significantly higher among the CRC group (p=0.001) and significantly higher among the UC-CRC group (p=0.001). Conclusion: the diagnostic performance of CEA, miRNA-21, and miRNA-92a in discriminating patients with colorectal cancer patients from ulcerative colitis patients were concluded